活检中Gleason 4级总长度在Gleason分级组2前列腺癌中的临床实用性
该研究纳入457例活检为Gleason分级组2/Gleason评分3+4=7且随后行根治性前列腺切除术的患者,比较三种量化Gleason 4级模式的方法与术后不良病理的关联。多变量分析显示所有量化方法均与不良病理风险增加显著相关(p<0.0001),其中Gleason 4级总长度(mm)的AUC提升最大(0.044,AUC 0.728,95%CI 0.663-0.793),决策曲线分析显示其临床净获益最大。结论支持将Gleason 4级量化纳入病理报告和风险预测模型。
要点
- Gleason 4级总长度是预测术后不良病理的最强量化指标。
- 所有Gleason 4级量化方法均与不良病理风险增加显著相关(p<0.0001)。
- 建议将Gleason 4级量化纳入Gleason分级组2患者的病理报告和风险模型。
核心结论
- 在Gleason分级组2前列腺癌患者中,活检Gleason 4级量化与根治性前列腺切除术后不良病理显著相关。
- Gleason 4级总长度(mm)在预测不良病理方面提供最大AUC提升和临床净获益。
研究设计与样本
- 回顾性纳入457例活检为Gleason分级组2且随后行根治性前列腺切除术的患者,仅分析复核穿刺点数≥12针者。
- 采用训练集/测试集方法和多变量逻辑回归评估三种Gleason 4级量化方法与不良病理的关联。
主要发现
- 多变量分析中所有Gleason 4级量化方法均与不良病理风险增加显著相关(p<0.0001),且均使AUC较基础模型提升。
- Gleason 4级总长度的AUC提升最大为0.044(AUC 0.728,95%CI 0.663-0.793)。
- 决策曲线分析显示加入Gleason 4级量化可增加临床净获益,其中Gleason 4级总长度净获益最大。
关键数值与推荐
- 不良病理定义为根治性前列腺切除术后Gleason评分≥4+3=7(Gleason分级组≥3),和/或任何前列腺外侵犯、精囊侵犯和/或淋巴结转移。
- 三种Gleason 4级量化方法包括:任一单针中Gleason 4级最大百分比、总体Gleason 4级百分比(Gleason 4级mm/总癌mm)、所有穿刺针中Gleason 4级总长度(mm)。
临床怎么用
- 病理报告应纳入Gleason 4级量化(尤其是所有穿刺针中Gleason 4级总长度),以辅助风险分层。
- 风险预测模型可考虑加入Gleason 4级总长度以提升对不良病理的预测能力。
局限性
- 研究为单中心回顾性设计,仅纳入穿刺点数≥12针且后续行根治性前列腺切除术的患者,存在选择偏倚可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: To our knowledge the ideal methodology of quantifying secondary Gleason pattern 4 in men with Grade Group 2/Gleason score 3 + 4 = 7 on biopsy remains unknown. We compared various methods of Gleason pattern 4 quantification and evaluated associations with adverse pathology findings at radical prostatectomy. MATERIALS AND METHODS: A total of 457 men with Grade Group 2 prostate cancer on biopsy subsequently underwent radical prostatectomy at our institution. Only patients with 12 or more reviewed cores were included in analysis. We evaluated 3 methods of quantifying Gleason pattern 4, including the maximum percent of Gleason pattern 4 in any single core, the overall percent of Gleason pattern 4 (Gleason pattern 4 mm/total cancer mm) and the total length of Gleason pattern 4 in mm across all cores. Adverse pathology features at radical prostatectomy were defined as Gleason score 4 + 3 = 7 or greater (Grade Group 3 or greater), and any extraprostatic extension, seminal vesical invasion and/or lymph node metastasis. A training/test set approach and multivariable logistic regression were used to determine whether Gleason pattern 4 quantification methods could aid in predicting adverse pathology. RESULTS: On multivariable analysis all Gleason pattern 4 quantification methods were significantly associated with an increased risk of adverse pathology (p <0.0001) and an increased AUC beyond the base model. The largest AUC increase was 0.044 for the total length of Gleason pattern 4 (AUC 0.728, 95% CI 0.663-0.793). Decision curve analysis demonstrated an increased clinical net benefit with the addition of Gleason pattern 4 quantification to the base model. The total length of Gleason pattern 4 clearly provided the largest net benefit. CONCLUSIONS: Our findings support the inclusion of Gleason pattern 4 quantification in the pathology reports and risk prediction models of patients with Grade Group 2/Gleason score 3 + 4 = 7 prostate cancer. The total length of Gleason pattern 4 across all cores provided the strongest benefit to predict adverse pathology features.
引用
- Dean LW, Assel M, Sjoberg DD, et al. Clinical Usefulness of Total Length of Gleason Pattern 4 on Biopsy in Men with Grade Group 2 Prostate Cancer. J Urol. 2019. PMID: 30076908. doi:10.1016/j.juro.2018.07.062
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。